Attachment IV - Page 9 
Hon. William D. Ruckleshaus 
March 12, 1984 
Page Two 
(3) What is HHS’s projection for FY '84 and FY '85 for the number of appli- 
cations it anticipates receiving for field scale releases? For commer- 
cial releases? 
(4) How does EPA plan to coordinate its activities with other regulatory 
and R&D programs in EPA? With the U.S. Department of Agriculture? 
With the National Institutes of Health? 
(5) EPA currently does not have sustantial expertise in genetic engineer- 
ing. How and on what timetable does EPA expect to develop its exper- 
tise in this field? To the extent EPA gets requests for release into 
the environment during the next six months, how will EPA handle such 
applications? During the next year? 
(6) How does think that the talent and expertise in genetic engineering 
currently available in the Federal Government can best be utilized to 
assure that research progress and commercialization of biotechnology 
proceed in a timely fashion, while providing for appropriate review to 
Insure public health and safety? Is additional legislation necessary 
for this purpose? 
I appreciate your attention to this request. If you have any questions, 
please contact Robert B. Nicholas, Staff Director/Counsel, or Dr. Morris Levin, 
LEGIS fellow, of the Investigations and Oversight Subcommittee staff at 
226-3636. 
Subcommittee on Investigations 
and Oversight 
AG/Ntk 
Enc I osure 
cc: John Moore 
Bernard Goldstein 
[521] 
